Standardtherapie der akuten und chronischen Hepatitis C

Literatur

• 1 Alberti A, Boccato S, Vario A. et al . Therapy of acute hepatitis C.  Hepatology. 2002;  36 (Suppl.) 195-200 (Übersicht)
• 2 Poynard T, Regimbeau C, Myers R P. et al . Interferon for acute hepatitis C.  Cochrane Database Syst Rev. 2002;  (1) CD000369 (Übersicht)
• 3 Camma C, Licata A, Craxi A. Interferon as treatment for acute hepatitis C: a meta-analysis.  Hepatology. 2002;  36 (Suppl.) 285A (III)
• 4 Jaeckel E, Cornberg M, Wedemeyer H. et al . Treatment of acute hepatitis C with interferon alfa-2 b.  N Engl J Med. 2001;  345 1452-1457 (Ib)
• 5 Gerlach J T, Diepolder H M, Zachoval R. et al . Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.  Gastroenterology. 2003;  125 (1) 80-88 (III)
• 6 Hofer H, Watkins-Riedel T, Janata O. et al . Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.  Hepatology. 2003;  37 60-64 (III)
• 7 Fattovich G, Giustina G, Favarato S. et al . A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.  J Hepatol. 1996;  24 38-47 (III)
• 8 Marcellin P, Boyer N, Gervais A. et al . Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy.  Ann Intern Med. 1997;  127 875-881 (IIb)
• 9 McHutchison J G, Davis G L, Esteban-Mur R. et al . Durability of sustained virologic response in patients with chronic hepatitis C after treatment with interferon (- 2 b alone or in combination with ribavirin.  Hepatology. 2001;  34 (Suppl.) 244A (IIa)
• 10 Poynard T, McHutchison J, Manns M. et al . Impact of pegylated interferon alfa-2 b and ribavirin on liver fibrosis in patients with chronic hepatitis C.  Gastroenterology. 2002;  122 1303-1313 (IIa)
• 11 Mathurin P, Moussalli J, Cadranel J F. et al . Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity.  Hepatology. 1998;  27 868-872 (III)
• 12 EASL International Consensus Conference on hepatitis C. Consensus statement.  J Hepatol. 1999;  31 (Suppl.) 3-8 (Übersicht)
• 13 National Institutes of Health consensus development conference statement . Management of hepatitis C: 2002.  Hepatology. 2002;  36 (Suppl.) 3-15 (Übersicht)
• 14 Camma C, Giunta M, Andreone P. et al . Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.  J Hepatol. 2001;  34 593-602 (Ia)
• 15 Wiley T E, McCarthy M, Breidi L. et al . Impact of alcohol on the histological and clinical progression of hepatitis C infection.  Hepatology. 1998;  28 805-809 (III)
• 16 Peters M G, Terrault N A. Alcohol use and hepatitis C.  Hepatology. 2002;  36 (Suppl.) 220-225 (III)
• 17 Zeuzem S, Franke A, Lee J H. et al . Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology.  Hepatology. 1996;  24 1003-1009 (III)
• 18 Gebo K A, Chander G, Jenckes M W. et al . Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review.  Hepatology. 2002;  36 (Suppl.) 84-92 (III)
• 19 Kozlowski A, Charles S A, Harris J M. Development of pegylated interferons for the treatment of chronic hepatitis C.  Biodrugs. 2001;  15 419-429 (Übersicht)
• 20 Zeuzem S, Heathcote J, Martin N. et al . Peginterferon alfa-2 a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy.  Expert Opin Investig Drugs. 2001;  10 2201-2213 (Übersicht)
• 21 Wang Y S, Youngster S, Grace M. et al . Structural and biological characterization of pegylated recombinant interferon alpha-2 b and its therapeutic implications.  Advanced Drug Delivery Reviews. 2002;  54 547-570 (Übersicht)
• 22 Di Bisceglie A M, Conjeevaram H S, Fried M W. et al . Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1995;  123 897-903 (Ib)
• 23 Bodenheimer H C Jr, Lindsay K L, Davis G L. et al . Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.  Hepatology. 1997;  26 473-477 (Ib)
• 24 Lau J Y, Tam R C, Liang T J. et al . Mechanism of action of ribavirin in the combination treatment of chronic HCV infection.  Hepatology. 2002;  35 1002-1009 (Übersicht)
• 25 Fried M W, Shiffman M L, Reddy K R. et al . Peginterferon alfa-2 a plus ribavirin for chronic hepatitis C virus infection.  N Engl J Med. 2002;  347 975-982 (Ib)
• 26 Hadziyannis S J, Sette H Jr, Morgan T. et al. PEGASYS International Study Group . Peginterferon alfa2 a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.  Ann Intern Med. 2004;  140 (5) 346-355 (Ib)
• 27 Manns M P, McHutchison J G, Gordon S C. et al . Peginterferon alfa-2 b plus ribavirin compared with interferon alfa-2 b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.  Lancet. 2001;  358 958-965 (Ib)
• 28 Keating G, Curran M. Peginterferon-alpha-2 a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.  Drugs. 2003;  63 701-730 (Übersicht)
• 29 Scott L J, Perry C M. Interferon-alpha-2 b plus ribavirin: a review of its use in the management of chronic hepatitis C.  Drugs. 2002;  62 507-556 (Übersicht)
• 30 Davis G L, Esteban-Mur R, Rustgi V. et al . Interferon alfa-2 b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.  N Engl J Med. 1998;  339 1493-1499 (Ib)
• 31 Camma C, Giunta M, Chemello L. et al . Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).  Hepatology. 1999;  30 801-807 (Ia)
• 32 Heathcote E J, Keeffe E B, Lee S S. et al . Re-treatment of chronic hepatitis C with consensus interferon.  Hepatology. 1998;  27 1136-1143 (Ib)
• 33 Alberti A, Chemello L, Noventa F. et al . Therapy of hepatitis C: re-treatment with alpha interferon.  Hepatology. 1997;  26 (Suppl.) 137S-142S (Übersicht)
• 34 Cheng S J, Bonis P A, Lau J. et al . Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: a meta-analysis of controlled and uncontrolled trials.  Hepatology. 2001;  33 231-240 (Ia)
• 35 Shiffman M L. Management of interferon therapy nonresponders.  Clin Liver Dis. 2001;  5 1025-1043 (Übersicht)
• 36 Shiffman M L, Hofmann C M, Contos M J. et al . A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.  Gastroenterology. 1999;  117 1164-1172 (Ib)
• 37 Mangia A, Leandro G, Helbling B. et al . Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials.  J Hepatol. 2004;  40 (3) 478-483 (Ia)
• 38 Berg T, Kronenberger B, Hinrichsen H. et al . Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial.  Hepatology. 2003;  37 (6) 1359-1367 (Ib)
• 39 Brillanti S, Levantesi F, Masi L. et al . Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.  Hepatology. 2000;  32 630-634 (Ib)
• 40 Teuber G, Pascu M, Berg T. et al . Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulfate in non-responders with chronic hepatitis C.  J Hepatol. 2003;  39 (4) 606-613 (Ib)
• 41 Zeuzem S, Herrmann E, Lee J H. et al . Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha-2 a.  Gastroenterology. 2001;  120 1438-1447 (III)
• 42 Zeuzem S, Lee J H, Franke A. et al . Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.  Hepatology. 1998;  27 1149-1156 (III)
• 43 Wong J B, Davis G L, McHutchison J G. et al . Clinical implications of testing viral response during ribavirin and peginterferon alfa-2 b treatment for chronic hepatitis C.  Hepatology. 2002;  36 (Suppl.) 281A (III)
• 44 Berg T, Sarrazin C, Herrmann E. et al . Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy.  Hepatology. 2003;  37 600-609 (III)
• 45 McHutchison J G, Gordon S C, Schiff E R. et al . Interferon alfa-2 b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.  N Engl J Med. 1998;  339 1485-1492 (Ib)
• 46 Fried M W. Side effects of therapy of hepatitis C and their management.  Hepatology. 2002;  36 (Suppl.) 237-244 (Übersicht)
• 47 Lunel F, Cacoub P. Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection.  J Hepatol. 1999;  31 (Suppl.) 210-216 (Übersicht)
• 48 Musselman D L, Lawson D H, Gumnick J F. et al . Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344 961-966 (Ib)
• 49 McHutchison J G, Manns M, Patel K. et al . Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.  Gastroenterology. 2002;  123 1061-1069 (III)